Back to Journals » Drug Design, Development and Therapy » Volume 11

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy

Authors Roman M, Chiu MW

Received 1 February 2017

Accepted for publication 12 April 2017

Published 7 July 2017 Volume 2017:11 Pages 2065—2075

DOI https://doi.org/10.2147/DDDT.S113683

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng

Michael Roman,1 Melvin W Chiu2

1David Geffen School of Medicine at UCLA, 2Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Abstract: Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA. The role of IL-17A in the pathogenesis of psoriasis, as well as the remarkable effectiveness of IL-17 inhibitors in the treatment of moderate-to-severe plaque psoriasis, is well established. The mechanism of action of brodalumab is unique in that it inhibits the IL-17 receptor compared to the two other currently FDA-approved IL-17 inhibitors, secukinumab and ixekizumab, which inhibit the IL-17A molecule itself. The efficacy of brodalumab in the treatment of moderate-to-severe plaque psoriasis has been demonstrated in phase 2 and 3 trials, and subsequently the FDA approved this medication in February 2017. Brodalumab was approved in Japan in July 2016 and approval is pending in Europe. The safety and adverse effects of brodalumab were reviewed across several clinical trials, which, similar to other IL-17 inhibitors, demonstrated increased rates of neutropenia and Candida infections. Brodalumab treatment, similar to ixekizumab and secukinumab, showed no improvement in inflammatory bowel disease patients, and on the contrary, more exacerbations were encountered. Suicidal ideation and behavior events have been reported with brodalumab treatment and are of significant concern. Brodalumab provides another highly effective treatment option for moderate-to-severe plaque psoriasis.

Keywords: brodalumab, biologics, IL-17, plaque psoriasis
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Profile of secukinumab in the treatment of psoriasis: current perspectives

Roman M, Madkan VK, Chiu MW

Therapeutics and Clinical Risk Management 2015, 11:1767-1777

Published Date: 2 December 2015

Psoriasis and comorbidities: links and risks

Ni C, Chiu MW

Clinical, Cosmetic and Investigational Dermatology 2014, 7:119-132

Published Date: 17 April 2014